BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-313@pharmaconomics
DTSTAMP:20260707T050223Z
DTSTART;VALUE=DATE:20260702
DTEND;VALUE=DATE:20260703
SUMMARY:NVS Approval — Itvisma
DESCRIPTION:A final FDA approval decision on Itvisma for spinal muscular atrophy (SMA) is expected Jul 2\, 2026.\n\nPrimary source: https://www.globenewswire.com/news-release/2026/07/02/3321085/0/en/Novartis-receives-European-Commission-approval-for-Itvisma-for-spinal-muscular-atrophy-SMA.html\n\nTrack it: https://www.pharmaconomics.com/e/313
URL:https://www.pharmaconomics.com/e/313
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:NVS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR